Dr. Jennifer Litton, a board-certified medical oncologist and professor of breast medical oncology at the University of Texas MD Anderson Cancer Center in Houston, where she is chief of the Section of Clinical Research and Drug Development for Breast Cancer. She also is a member of the Breast Immuno-Oncology Task Force of the National Cancer Institute. At the American Association for Cancer Research virtual annual meeting, Dr. Litton presented results from the EMBRACA trial, looking at using Talzenna (chemical name: talazoparib), a type of medicine called a PARP inhibited, to treat advanced-stage HER2-negative breast cancer in people with a BRCA1 or BRCA2 mutation. She joins us today to talk about the results, especially the patient-reported outcomes, which showed that people treated with Talzenna had better quality of life than people treated with chemotherapy. Listen to the podcast to hear Dr. Litton explain: what a PARP inhibitor is and how it works how quality of life was better for people treated with Talzenna compared to chemotherapy why she thinks Talzenna is a good treatment option for people diagnosed with metastatic HER2-negative breast cancer who also have a BRCA1 or a BRCA2 mutation Running time: 14:04

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related